AXSM240816C105000
- 0.35
- 0.000.00%
Axsome Therapeutics Newsroom
Axsome Therapeutics Price Target Maintained With a $131.00/Share by RBC Capital
Axsome Therapeutics Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Axsome Therapeutics Analyst Ratings
B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
Axsome Therapeutics Analyst Ratings
Mizuho Reiterates Buy on Axsome Therapeutics, Maintains $106 Price Target
Axsome Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Ultragenyx Pharmaceutical (RARE)
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), Werewolf Therapeutics (HOWL)
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intuitive Surgical (ISRG) and Silence Therapeutics (SLN)
Hold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization Prospects
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106
Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)
Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials
Axsome Therapeutics Analyst Ratings
Buy Rating Affirmed on Axsome Therapeutics Due to Strong Auvelity Sales and Promising Alzheimer's Treatment Pipeline
Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital